| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | IL15RA |
| Entrez GeneID | 3601 |
| clone | 5F10D9 |
| WB Predicted band size | 28.2kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CD215 (AA: extra 31-205) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CD215(IL-3Rα/CD123)抗体的3篇代表性文献，简要整理如下：
1. **文献名称**：*Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform*
**作者**：Zheng, Y. et al.
**摘要**：研究开发了一种双特异性抗体，靶向CD215(CD123)和T细胞表面CD3.用于治疗急性髓系白血病(AML)。实验证明该抗体可有效激活T细胞杀伤AML细胞，并在小鼠模型中抑制肿瘤生长。
2. **文献名称**：*CD123-antibody-drug conjugate targeting of acute myeloid leukemia*
**作者**：Kovtun, Y. et al.
**摘要**：报道了一种CD215抗体-药物偶联物(ADC)，通过将抗CD123单抗与细胞毒素结合，选择性杀伤高表达CD123的白血病细胞。临床前数据显示其在AML异种移植模型中显著延长生存期。
3. **文献名称**：*The role of CD123 in the tumor microenvironment and targeted therapy in hematologic malignancies*
**作者**：Testa, U. et al.
**摘要**：综述了CD215(CD123)在血液肿瘤微环境中的生物学功能，并总结了靶向CD123的单克隆抗体、CAR-T细胞及小分子抑制剂的研究进展，强调其作为治疗靶点的潜力。
注：CD215(IL-3Rα/CD123)在部分文献中可能以“CD123”为主要命名。若需更早期或特定方向的研究，可进一步补充。
CD215 antibody targets the CD215 antigen, also known as the interleukin-2 receptor β-chain (IL2RB), a key component of the interleukin-2 (IL-2) and interleukin-15 (IL-15) receptor complexes. IL2RB is a type I transmembrane protein that pairs with the common γ-chain (γc, CD132) to form intermediate-affinity receptors for IL-2 and IL-15. In combination with the α-chain (CD25), it forms the high-affinity IL-2 receptor critical for T cell activation and regulatory T cell (Treg) function. CD215 is expressed on immune cells, including activated T cells, natural killer (NK) cells, and memory T cells, playing a central role in lymphocyte proliferation, survival, and immune homeostasis.
Research on CD215 antibodies has focused on their therapeutic and diagnostic potential. In autoimmune diseases and transplant rejection, blocking IL2RB signaling may suppress pathological immune responses. Conversely, in cancer immunotherapy, enhancing IL-2/IL-15 signaling through CD215 could boost antitumor immunity by promoting NK and cytotoxic T cell activity. CD215 antibodies are also used as tools to study receptor dynamics, ligand binding, and downstream signaling pathways like JAK-STAT. Challenges include balancing therapeutic efficacy with potential side effects, such as unintended immune activation or suppression. Recent advances in antibody engineering have improved specificity and reduced off-target effects, positioning CD215-targeting agents as promising candidates for modulating immune responses in clinical settings.
×
